As of June 30, 2025, cash and cash equivalents totaled $22.3 million. The Company believes that it has sufficient resources to fund operations into the second half of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics announces publication of OLC trial data
- Unicycive Regains Nasdaq Compliance After Stock Split
- Unicycive Therapeutics regains compliance with Nasdaq bid price requirement
- Unicycive Therapeutics approval delay ‘not a surprise,’ says Noble Capital
- Unicycive Receives FDA CRL for New Drug Application